83 related articles for article (PubMed ID: 22192642)
1. Treatment duration (persistence) of basal insulin supported oral therapy (BOT) in Type-2 diabetic patients: comparison of insulin glargine with NPH insulin.
Quinzler R; Ude M; Franzmann A; Feldt S; Schüssel K; Leuner K; Müller WE; Dippel FW; Schulz M
Int J Clin Pharmacol Ther; 2012 Jan; 50(1):24-32. PubMed ID: 22192642
[TBL] [Abstract][Full Text] [Related]
2. Different persistence on initial basal supported oral therapy in Type 2 diabetics is associated with unequal distributions of insulin treatment regimens under real-life conditions in Germany.
Pfohl M; Dippel FW; Kostev K; Fuchs S; Kotowa W
Int J Clin Pharmacol Ther; 2010 Nov; 48(11):761-6. PubMed ID: 20979936
[TBL] [Abstract][Full Text] [Related]
3. Treatment persistence after initiating basal insulin in type 2 diabetes patients: A primary care database analysis.
Pscherer S; Chou E; Dippel FW; Rathmann W; Kostev K
Prim Care Diabetes; 2015 Oct; 9(5):377-84. PubMed ID: 25701545
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study.
Haukka J; Hoti F; Erästö P; Saukkonen T; Mäkimattila S; Korhonen P
Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1326-35. PubMed ID: 24150837
[TBL] [Abstract][Full Text] [Related]
5. Resource consumption and costs of treatment in patients with type 1 diabetes under intensified conventional therapy under German real-life conditions.
Kostev K; Dippel FW; Bierwirth R
J Diabetes Sci Technol; 2013 May; 7(3):736-42. PubMed ID: 23759407
[TBL] [Abstract][Full Text] [Related]
6. Risk of diabetic foot ulceration during treatment with insulin glargine and NPH insulin.
Kostev K; Dippel FW; Rockel T; Siegmund T
J Wound Care; 2012 Oct; 21(10):483-4, 486-9. PubMed ID: 23103482
[TBL] [Abstract][Full Text] [Related]
7. [POET2 registry: Comparison of annual direct medical costs of treating type 2 diabetes after addition of insulin NPH or insulin glargine to oral antidiabetic therapy in the Czech Republic].
Kvapil M; Žďarská DJ; Suchopár J; Prokeš M; Brož J
Vnitr Lek; 2015 Jan; 61(1):24-32. PubMed ID: 25693613
[TBL] [Abstract][Full Text] [Related]
8. Real-world therapeutic benefits of patients on insulin glargine versus NPH insulin.
Fiesselmann A; Wiesner T; Fleischmann H; Bramlage P
Acta Diabetol; 2016 Oct; 53(5):717-26. PubMed ID: 27093968
[TBL] [Abstract][Full Text] [Related]
9. Treatment persistence in the use of basal insulins in Poland and Germany
.
Rathmann W; Czech M; Franek E; Kostev K
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):119-125. PubMed ID: 27879196
[TBL] [Abstract][Full Text] [Related]
10. Health economic evaluation of insulin glargine vs NPH insulin in intensified conventional therapy for type 1 diabetes in Germany.
Pfohl M; Schädlich PK; Dippel FW; Koltermann KC
J Med Econ; 2012; 15 Suppl 2():14-27. PubMed ID: 22812690
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study comparing neutral protamine hagedorn insulin with glargine as basal therapy in prednisone-associated diabetes mellitus in hospitalized patients.
Dhital SM; Shenker Y; Meredith M; Davis DB
Endocr Pract; 2012; 18(5):712-9. PubMed ID: 22784834
[TBL] [Abstract][Full Text] [Related]
12. All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine.
Strandberg AY; Hoti FJ; Strandberg TE; Christopher S; Haukka J; Korhonen P
PLoS One; 2016; 11(3):e0151910. PubMed ID: 27031113
[TBL] [Abstract][Full Text] [Related]
13. Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and igf-I receptor signaling.
Varewijck AJ; Yki-Järvinen H; Schmidt R; Tennagels N; Janssen JA
Diabetes; 2013 Jul; 62(7):2539-44. PubMed ID: 23569175
[TBL] [Abstract][Full Text] [Related]
14. [Switching of NPH insulin to glargine therapy in a cohort of diabetic patients: observational study].
Maia FF; Melo FJ; Araújo IM; Araújo LR
Arq Bras Endocrinol Metabol; 2007 Apr; 51(3):426-30. PubMed ID: 17546241
[TBL] [Abstract][Full Text] [Related]
15. Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin.
Stürmer T; Marquis MA; Zhou H; Meigs JB; Lim S; Blonde L; Macdonald E; Wang R; Lavange LM; Pate V; Buse JB
Diabetes Care; 2013 Nov; 36(11):3517-25. PubMed ID: 23877991
[TBL] [Abstract][Full Text] [Related]
16. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
Rosenstock J; Park G; Zimmerman J;
Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511
[TBL] [Abstract][Full Text] [Related]
17. [Costs of diabetes care and treatment satisfaction in type 2 diabetes patients treated with a basal-bolus (ICT) insulin regimen in outpatient care: results of the LIVE-COM study].
Bierwirth RA; Kohlmann T; Moock J; Holle R; Landgraf W
Med Klin (Munich); 2010 Nov; 105(11):792-801. PubMed ID: 21136237
[TBL] [Abstract][Full Text] [Related]
18. Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies.
Duckworth W; Davis SN
J Diabetes Complications; 2007; 21(3):196-204. PubMed ID: 17493554
[TBL] [Abstract][Full Text] [Related]
19. Different injection frequencies of basal insulins in type 2 diabetes patients under real-life conditions: a retrospective database analysis.
Rathmann W; Dippel FW; Kostev K
J Diabetes Sci Technol; 2013 Sep; 7(5):1354-8. PubMed ID: 24124964
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
Levin P; Wei W; Wang L; Pan C; Douglas D; Baser O
Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
